Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.
Statistics from Altmetric.com
Funding: We are grateful for financial support from the Stan and Madelle Rosenfeld Family Trust.
Competing interests: JTR, EBS and PAK disclose a relationship with Genentech, in that Genentech is sponsoring the follow-up Phase I/II prospective study.
Ethics approval: Ethics approval was provided by the Institutional Review Board, Oregon Health & Science University.
Patient consent: Obtained.